Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Retatrutide for Sale > GMP factory sale High Purity Retalutide peptide powder cas 2381089-83-2 peptide
GMP factory sale High Purity Retalutide peptide powder cas 2381089-83-2 peptide buy - large image1
GMP factory sale High Purity Retalutide peptide powder cas 2381089-83-2 peptide buy - image1
GMP factory sale High Purity Retalutide peptide powder cas 2381089-83-2 peptide buy - image2
GMP factory sale High Purity Retalutide peptide powder cas 2381089-83-2 peptide buy - image3

GMP factory sale High Purity Retalutide peptide powder cas 2381089-83-2 peptide

7500 Inquiries

Unit Price: Get Latest Price
CAS No.:

2381089-83-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

BEIJING

Brand:

Bovita

Packaging:

10g/aluminium foil bag

Sample Available:

Yes

Price valid (until):

2026-05-10

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
10 days
Qualification:
Main Products:

Peptides Powder,Dietary Supplements Powder,APIs Active Pharmaceutical Ingredientsal ingredient,Pharmaceutical Intermediates,Food Additives,Pharmaceuticals Machinery

  • Product Details

  • Seller Information

  • Inquiry History

  • Description
    Retatrutide Powder (CAS 2381089-83-2)
    Product Name: Retatrutide Powder
    CAS Number: 2381089-83-2
    Molecular Formula: C₂₇₁H₄₁₉N₇₅O₈₁S
    Molecular Weight: 5985.9 g·mol⁻¹
    Class: GLP-1R / GIPR / GCGR triple agonist peptide

    1. Product Description

    Retatrutide is a novel long-acting triple agonist of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors. As a synthetic peptide, it combines the synergistic effects of three hormones, exhibiting more potent metabolic regulation capabilities compared to dual agonists.
    Our Retatrutide Powder is supplied as a white to off-white lyophilized powder with ultra-high purity and excellent stability. It is manufactured in a GMP-compliant cleanroom environment, undergoing strict quality control to ensure batch-to-batch consistency, which meets the high standards of pharmaceutical R&D and industrial production.

    2. Key Specifications

    Item
    Specification
    Assay (HPLC)
    ≥98.0%
    Appearance
    White to off-white lyophilized powder
    Water Content
    ≤5.0%
    Total Impurities
    ≤2.0%
    Single Unknown Impurity
    ≤0.5%
    Peptide Purity
    ≥98.0%
    Bacterial Endotoxins
    ≤5 EU/mg
    pH
    5.0 – 7.0 (in solution)

    3. Mechanism of Action

    • Simultaneously activates GLP-1R, GIPR, and GCGR, achieving synergistic regulation of glucose metabolism, energy balance, and body weight.
    • Enhances glucose-dependent insulin secretion, suppresses glucagon release, and effectively reduces fasting and postprandial blood glucose levels.
    • Delays gastric emptying, inhibits appetite, and promotes significant weight loss by regulating central appetite control centers.
    • Stimulates energy expenditure through GCGR activation, further optimizing metabolic efficiency and improving lipid profiles.
    • Features a long half-life, supporting once-weekly administration in finished pharmaceutical formulations for improved patient compliance.

    4. Main Applications

    • Pharmaceutical API: Used in the R&D and production of injectable preparations for the treatment of type 2 diabetes mellitus, chronic weight management, and related metabolic disorders.
    • Research & Development: Applied in preclinical pharmacology, toxicology, formulation optimization, and biomedical research on metabolism and obesity.
    • Scientific Research: Suitable for studies on GLP-1/GIP/GCGR signaling pathways, metabolic regulation mechanisms, and the development of novel peptide therapeutics.

    5. Our Advantages

    • Ultra-High Purity: HPLC ≥98.0%, with low impurity content, ensuring safety and reliability for pharmaceutical R&D and formulation.
    • Stable Quality: Strict production process control and comprehensive analytical testing (COA, HPLC, MS, NMR) provided for each batch.
    • Professional Manufacturing: Produced in a GMP-compliant cleanroom with strict contamination control, meeting international pharmaceutical standards.
    • Cold-Chain Protection: Specialized lyophilized packaging and cold-chain transportation to maintain peptide stability and activity.
    • Complete Documentation: Full technical dossiers, including COA, MSDS, stability data, and analytical reports, available upon request.

    6. Storage & Handling

    • Storage: Store at ≤ -20°C, protected from light, heat, and moisture to avoid degradation.
    • Transport: Transport with dry ice or professional cold-chain packaging to maintain low-temperature stability.
    • Shelf Life: 2 years under proper storage conditions.
    • Avoid repeated freeze-thaw cycles, as this may affect peptide activity.
    • Handling: Wear protective gloves, clothing, and goggles; operate in a well-ventilated area to avoid inhalation and skin/eye contact.

    7. Safety & Compliance Notice

    • For research and industrial manufacturing use only.
    • Not for direct human or animal administration.
    • Strictly comply with local laws and regulations regarding peptide APIs, pharmaceutical raw materials, and controlled substances.
    • Full MSDS (Material Safety Data Sheet) with detailed safety information is provided with each order.

    8. Packaging & Shipping

    • Packing: 1g, 5g, 10g, 50g, 100g, 1kg sealed lyophilized vials or aluminum foil bags; customizable packaging available based on order quantity.
    • MOQ: Flexible, supporting small-batch R&D orders and large-scale bulk orders.
    • Lead Time: In-stock items shipped within 2–3 working days; custom orders negotiated based on quantity.
    • Shipping: Cold-chain transport via DHL, FedEx, UPS, or international air/sea freight, with full tracking provided.

    Why Choose Us? We are a professional manufacturer and supplier of high-quality peptide APIs, focusing on the global pharmaceutical and research markets. Our Retatrutide Powder is produced with advanced technology and strict quality control, ensuring superior performance and reliability. We offer competitive pricing, flexible MOQs, and professional after-sales service to support your business development. Contact us today for a quote, free sample, or more technical information.
    Shop GMP factory sale High Purity Retalutide peptide powder cas 2381089-83-2 peptide-Detailed Image 1 Shop GMP factory sale High Purity Retalutide peptide powder cas 2381089-83-2 peptide-Detailed Image 2
    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Polypeptide

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptides Powder,Dietary Supplements Powder,APIs Active Pharmaceutical Ingredientsal ingredient,Pharmaceutical Intermediates,Food Additives,Pharmaceuticals Machinery

    Location:

    Room 403 No.62 of Shan Shui Huihao Gardan, Dou Dian Town,Fangshan District, Beijing,China

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    10 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    11-50

    Year of Establishment:

    2026

    Bovita is a forward-thinking biotech startup specializing in high-purity peptide products and premium dietary supplement raw materials. Rooted in the rigorous standards of China’s pharmaceutical and chemical industry, we are dedicated to bridging scientific excellence with global wellness demands, with a core focus on serving the North American and European markets.

      Company Profile  


  • Inquiry History
    7500 Inquiries
    Country Product Purchase Quantity Date Posted
    Malaysia

    Retatrutide

    20 MG Oct 28, 2026
    United States

    Retatrutide

    2 MT Oct 29, 2026
    United States

    Retatrutide

    1 MT Oct 29, 2026
    United Kingdom

    Retatrutide

    1 PCS Oct 28, 2026
    United States

    Retatrutide

    30 MT Oct 28, 2026
    United Kingdom

    Retatrutide

    10 MT Oct 28, 2026
    Norway

    Retatrutide

    100 G Oct 28, 2026
    United States

    retatrutide

    30 MG Oct 28, 2026
    Czech

    Retatrutide

    10 MG Oct 28, 2026
    Austria

    retatrutide

    30 MG Oct 28, 2026
    United States

    Retatrutide

    100 KG Oct 28, 2026
    Malta

    Retatrutide

    10 MT Oct 28, 2026
    United States

    Retatrutide

    600 MG Oct 28, 2026
    United States

    Retatrutide

    500 G Oct 28, 2026
    United States

    Retatrutide

    60 G Oct 28, 2026
    Croatia

    Retatrutide

    10 MG Oct 28, 2026
    United States

    Retatrutide

    200 MG Oct 28, 2026
    Sweden

    Retatrutide

    10 MG Oct 28, 2026
    United States

    Retatrutide

    1 G Oct 27, 2026
    United Kingdom

    Retatrutide

    10 MG Oct 27, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.